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Abstract
Background: Optical imaging (OI) techniques such as bioluminescence and fluorescence imaging have been widely used to
track diseases in a non-invasive manner within living subjects. These techniques generally require bioluminescent and
fluorescent probes. Here we demonstrate the feasibility of using radioactive probes for in vivo molecular OI.
Methodology/Principal Findings: By taking the advantages of low energy window of light (1.2–3.1 eV, 400–1000 nm)
resulting from radiation, radionuclides that emit charged particles such as b
+ and b
2 can be successfully imaged with an OI
instrument. In vivo optical images can be obtained for several radioactive probes including 2-deoxy-2-[
18F]fluoro-D-glucose
([
18F]FDG), Na
18F, Na
131I,
90YCl3 and a
90Y labeled peptide that specifically target tumors.
Conclusions/Significance: These studies demonstrate generalizability of radioactive OI technique. It provides a new
molecular imaging strategy and will likely have significant impact on both small animal and clinical imaging.
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Introduction
Molecular imaging is a relatively new yet fast growing research
discipline. Practical molecular imaging enables researchers to study
diseases non-invasively in living subjects at the molecular level
[1,2,3,4]. Numerous studies have demonstrated that molecular
imaging techniques play a central role in the era of personalized
medicine. A variety of imaging modalities have been developed that
provide functional and anatomical information of diseases in living
small animals and patients. Such modalities include positron
emission tomography (PET), single photon emission computed
tomography (SPECT), optical imaging (OI, bioluminescence and
fluorescence), magnetic resonance imaging (MRI), ultrasound (US),
and computed tomography (CT) [1,2].
OI has rapidly gained popularity in molecular imaging. It is an
inexpensive imaging technique due to the low costs of detection
devices. The technique is easy to learn and use and interpretation of
the images is generally straightforward. Imaging in the near-
infrared (NIR) regionhasadvantagesof improvedtissuepenetration
and low tissue autofluorescence which enhances target to
background ratios [5]. While OI generally detects low energy light
(visible or near-infrared light) emitted from bioluminescence or
fluorescence probes, radioactive molecular probes are traditionally
imaged with PET, SPECT or gamma (c) cameras that detect high
energy c rays [1]. We hypothesized that radionuclide radiation in
the low energy window of light (1.2–3.1 eV, 400–1000 nm) could
be imaged using OI techniques and be especially valuable for
molecular OI. Thus we examined a variety of radionuclides with
different types of emission properties (b
+, b
2 or c) using a
commercially available OI instrument for in vitro and in vivo optical
imaging. During the preparation of this manuscript, Robertson et
al. successfully demonstrated that high-energy b
+ emitters,
18Fa n d
13N, could be used for optical imaging [6]. This pioneer work
provides a solid foundation of using PET radioisotopes for optical
imaging. Our study further evaluated a variety of radionuclides
(b
+, b
2 and c emitters) for optical imaging. In vivo optical images
can be obtained for several radioactive probes such as 2-deoxy-2-
[
18F]fluoro-D-glucose ([
18F]FDG), Na
18F, Na
131I,
90YCl3 and a
90Y
labeled tumor targeting peptide. The results presented here bridge
the subfields of imaging by visualizing radioactive probes with OI.
Ourstudydemonstratesthefeasibilityofmolecularimagingofliving
subjects using OI modalities in conjunction with a wide diversity of
radioactive probes.
Results
Radioactive Materials That Can Be Used for OI
ToestablishOIasatechniquesuitablefordetectingabroadrange
of radionuclides, we surveyed the detectability of varying amounts of
commonly used radionuclides by an IVIS Spectrum OI system.
These radionuclidesincluded b
+emitters(
18Fa n d
64Cu),b
2emitters
(
131I,
90Y, and
177Lu), and c emitters [
111In (also electron capture)
and
99mTc]. With the exception of
99mTc, all tested radionuclides
provided optical signals with good sensitivity with 1–5 min
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9470acquisition time (Fig. 1A). This encouraging result clearly verified
ourhypothesis.Undertheconditionsusedinthestudies,goodsignal-
to-noise (S/N) ratios (.20 for
18Fa n d.7f o r
131I) were observed
with 0.1 mCi of radioactivity for
18Fa n d
131I, while 0.01 mCi of
90Y
could bedetected with a S/N of over 6. Theplot of averageradiance
vs. radioactive intensity for these radionuclides (Fig. 1B) provided
radionuclide’s imaging sensitivity as K values of the slopes.
Obviously, the pure b
2 emitter
90Y has the highest sensitivity
among all the radionuclides evaluated, and the detection sensitivity
of
18Fa n d
131I was ranked as 2
nd and 3
rd, respectively. Finally, the
Figure 1. Optical signals are detectable by OI instruments and have a continuous spectrum. (A) Most nuclides, except
99mTc, provide OI
signals with sensitivity within as low as 0.004–0.370 MBq (0.1–10 mCi) range. (
18F: 5, 2, 1, 0.1 mCi;
131I: 10, 5, 1, 0.1 mCi;
90Y: 5, 1, 0.2, 0.01 mCi;
64Cu: 10, 5,
1, 0.1 mCi;
177Lu: 10, 5, 2, 0.5 mCi;
111In: 10, 5, 1, 0.5 mCi;
99mTc: 20, 10, 5 mCi ). (B) Detection sensitivity of different radionuclides. Radionuclides with a
higher K value have stronger signal intensity. (C) Similar spectra were ovserved from different radionuclides. Results are presented as the ratio of
photons detected using a narrow band emission filter (20nm bandwidth) versus total photons detected without a filter. (D, E) Shielding tests (D) and
quantification analysis of imaging signals (E).
doi:10.1371/journal.pone.0009470.g001
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99mTc was undetectable even when high radioactivity
(20 mCi) was applied, suggesting that OI signal was not caused by c
rays (Fig. 1A).
IVIS Spectrum system provides us with the ability to measure
the OI imaging signal intensities at different wavelengths (from
490 to 850 nm). It was found that the total OI signals produced by
these radionuclides were actually contributed by light with
continuous wavelengths as monitored by the instrument. For the
radionuclides tested, the percentages of optical signal intensity at
different wavelengths vs. wavelength were shown in Fig. 1C. All
of these radionuclides shared a similar distribution pattern,
indicating the same mechanism for light production. Peak light
intensity was observed at 490–540 nm, with slow reduction from
540 to 700 nm, remaining flat from 700 nm onwards (Fig. 1C).
To further demonstrate that OI signals were not attributed to b
+
or b
2 particles or c high energy radiation directly, white and black
papers were used to cover the surface of the radioactive samples. It
was found that the light signal could be significantly blocked by the
coverage of a piece of white or black paper, and black paper also
showed better OI signal shielding ability than white paper (Fig. 1D
and E). Therefore, the optical signals detected were not from high
energy b
+ or b
2 particle which can penetrate paper, but from the
low energy optical photons that can be severely affected by the
opacity of the covered material. Limited penetrability, a common
disadvantage of OI, provided helpful information in determining
the nature of signals detected by optical camera. It is worth noting
that although optical signals can be significantly reduced by white
paper, they are not completely blocked. The photons that
penetrate through barrier can still be useful for in vivo imaging.
The optical signal depends on many factors such as the amount of
radioactivity, depth, tissue opacity, and tissue type.
Phantom Imaging Study
To further explore the potential of using radioactive probes for
OI, phantom imaging study was performed to determine the spatial
resolutionsofthethreemostsensitiveradionuclidesstudied(
18F,
131I
and
90Y). For all three radionuclides, 1.2 mm spatial resolution was
achieved (Fig. 2A, B and C). The detection resolution reported for
PET and SPECT radionuclides is in the range of 1–2 mm [1]. Pure
b
2 emitter
90Y has very poor resolution (in cm range) when SPECT
or c cameras are used for imaging of its high energy radiation
[7,8,9]. The results of phantom study demonstrated that the
radioactiveOIcouldbeusedforlivingsubjectimagingbecause ofits
high spatial resolution.
In Vivo Radioactive OI with a b
+ Emitter,
18F
In vivo radioactive OI was first demonstrated by using two well-
known PET probes, 2-deoxy-2-[
18F]fluoro-D-glucose ([
18F]FDG)
and Na
18F. [
18F]FDG has been widely used for imaging of tumor
metabolism [2,10,11], while Na
18F accumulates in the bone [11].
In this study, a group of mice (n=3) were implanted with firefly
luciferase (FLuc) transfected rat C6 glioma cells (C6-FLuc). A day
prior to the radioactive imaging, the mice were injected with
luciferin and bioluminescent OI was performed to verify the
presence of the tumor (Fig. 3A). [
18F]FDG was injected in he mice
bearing C6-FLuc glioma and imaged sequentially with IVIS
Spectrum (Fig. 3B) and microPET (Fig. 3C). [
18F]FDG was
preferentially localized and was retained in C6-FLuc tumors, as
clearly shown in both radioactive OI and microPET imaging
technique (Fig. 3B and C). High signals from bladder and brain
were also observed by both modalities. Heart, on the other hand,
was hardly visible in the radioactive OI because of its location
deep inside of the murine body. After we sacrificed and opened the
thorax of the mice, the heart was easily identified (Fig. 3D, yellow
arrow). To further characterize the distribution of [
18F]FDG using
radioactive OI, tumors and normal organs and tissues were
removed from the sacrificed mice and subjected to optical
imaging. High activity was mainly observed from the tumor and
heart tissue samples (Fig. 3E).
Quantitative analysis of both radioactive OI and microPET
images was performed. The OI intensities in the tumor and the
normal tissue as a function of time for [
18F]FDG was depicted in
Fig. 3F, while accumulation of radioactivity in tumor and muscle
over time was shown in Fig. 3G. It was found that radioactive OI
and microPET imaging provided similar information with regards
to [
18F]FDG uptake and kinetics in tumor and muscle (Fig. 3F
and G). The tumor uptake of [
18F]FDG increased significantly
(P,0.05) over time (from 0.5–2 h) for both modalities. Finally, in
order to further evaluate the quantitative analysis data obtained
from radioactive OI, correlation analysis was performed for the
tumor uptakes obtained from the two imaging modalities. Good
correlation was seen between the radioactive OI signal intensities
and microPET images derived tumor uptakes (Fig. 3H,r
2 over
0.90 for the analyses). This result illustrated the promise of
radioactive OI as a tool for semi-quantitative analysis of the
radioactive probe biodistribution.
The bone–seeking PET probe, Na
18F, was also used for
radioactive OI and microPET imaging studies to further confirm
the use of radioactive probes for molecular OI. High and
consistent imaging signals were observed in the bone structures
(vertebral column, cranium, etc.) in both imaging modalities
(Fig. 4A, B). The quantification analysis of the optical and PET
images was also performed and the results were shown in Fig. 4C
and D. Similar in vivo kinetics of Na
18F were observed using both
PET and radioactive OI.
Figure 2. Phantom imaging studies with radioactive OI and PET. (A–C) Radioactive OI of
18F,
131I and
90Y phantoms.
doi:10.1371/journal.pone.0009470.g002
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2 Emitter,
131I
Iodine ion accumulates in the thyroid, and Na
123/131I has been
widely used for imaging thyroid function and sodium iodide
symporter as well as for treating thyroid cancer [12,13,14].
We tested the SPECT probe, Na
131I, for thyroid radioactive OI.
Na
131I SPECT/CT fusion images shown in Fig. 5A (coronal
image) and B (sagittal image) clearly displayed the mouse bone
anatomic structure (brown-red color) and the localization of the
probe in the thyroid and abdomen region (green color, thyroid
was indicated by an arrow). Radioactive OI showed the
accumulation of the tracer in the thyroid and bladder as well,
with signal observable at an earlier time point post injection (p.i.).
The thyroid activity slowly increased, while the activity in the
bladder cleared out at later time points (Fig. 5C). At the end of
the OI study, the mice were sacrificed and the neck and chest
areas were opened to expose the internal organs. The thyroid was
clearly differentiated (Fig. 5D). Quantitative analysis of OI
demonstrated accumulation and retention of Na
131Ii nt h e
thyroid (Fig. 5E).
Radioactive OI with a Pure b
2 Emitter,
90Y
Arg-Gly-Asp (RGD) coupled with bombesin (BBN) peptide
(RGD-BBN) analogs were recently reported as heterodimeric
peptides for dual targeting of integrin avb3 and gastrin-releasing
peptide receptor (GRPR). Radiolabeled (
64Cu,
18F,
68Ga, etc.)
RGD-BBN peptides have been reported for PET imaging
of human prostate cancer in a PC3 tumor mice model
[15,16,17]. We labeled 1,4,7,10-tetraazacyclododecane-1,4,7,
10-tetraacetic acid (DOTA) conjugated RGD-BBN with
90Y
and tested
90Y-DOTA-RGD-BBN with radioactive OI. As
shown in Fig. 6A, PC3 tumors were clearly visible with good
tumor-to-background contrast at 1 and 4 h p.i. Also observed
were a high accumulation of the probe in the kidneys at 0.2 h
p.i., and in bladder at 0.5 and 1 h p.i. (Fig. 6A) .F o rm i c ec o -
injected with a large excess of RGD and BBN peptides, the
tumors were hardly visible on optical images at 1 h p.i. (Fig. 6C).
Quantification analysis of optical images showed the kinetic of
tumor targeting (Fig. 6B) and significantly lower tumor uptake
for the probe co-injected with the cold analog at 1 h p.i. (P,0.05)
(Fig. 6D).
Mice injected with
90YCl3 (1.8–2.0MBq each) were also
optically imaged at different time points p.i. (Fig. 6E). It could
be clearly seen that
90Y accumulated in the liver as well as in the
bone. High activity in the bladder suggested the clearance route of
this agent. The results obtained by the radioactive OI agree well
with the previous reports which measured the in vivo behavior of
90YCl3 by biodistribution study [18].
Figure 3. In vivo radioactive OI of [
18F]FDG in comparison with microPET. (A) Bioluminescence image of a nude mouse bearing C6-FLuc
tumor. (B,C) Radioactive OI and microPET imaging of a nude mouse bearing C6-FLuc tumor injected via tail vein with [
18F]FDG at 0.5, 1, 2 h p.i. (D,E)
Radioactive OI of the mouse after opening the thorax (D) and exposure the organs (E) at 2.1 h p.i. (F–H) Quantitative analysis of radioactive OI (F)
and microPET (G) results and their correlation (H).
doi:10.1371/journal.pone.0009470.g003
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Developingnovel imaging techniques and instrumentshasbeena
major effort in the molecular imaging field. OI is a novel technique
with many good characteristics such as high sensitivity, low-cost,
ease of use, relatively high-throughput, and short acquisition time
[1]. Recent advances in optical imaging instruments and molecular
probes have made it an excellent tool for both small animal research
and clinics. In this study, we demonstrate systematically that OI
techniques can also be used to image visible and near-infrared light
produced by radioactive materials. This would make OI a modality
of choice for evaluation of bioluminescent, fluorescent and
radioactive probes.
The success of using radionuclides for OI as demonstrated here is
expected to have a major impact to the molecular imaging field. First,
radioactive agents are traditionally studied by PET, SPECT or c
cameras, which are expensive, hard to maintain and not widely
available to many researchers. Our results clearly show that the
commercially available OI instrument can be used for studying
radioactive probes possessing both b
+ and b
2-emitting radionuclides,
as well as for bioluminescence and fluorescence probes. Considering
much lower cost and wider accessibility of the OI instruments than
that of PET and SPECT, radioactive probe development will likely
be dramatically accelerated by using this approach. Optical imaging
systems such as IVIS can image up to five animals simultaneously,
while small animal PET and SPECT may only image one mouse at a
time. The high throughput manner of OI equipments will also help to
improve the speed of radioactive probe development.
Although OI is an important tool in animal research, its clinical
applications have been severely hampered by very limited OI
probes approved by the Food and Drug Administration (FDA). So
far only iodocyanine green dye (IC-Green) has been approved for
use in humans [19]. On the other hand, radioactive imaging has a
longer history in biomedical imaging and has been widely used in
clinics for the past several decades. Many FDA approved SPECT
and PET probes including [
18F]FDG have been developed for
imaging different diseases and molecular targets. New applications
for these radioactive probes may be developed in conjunction with
radioactive OI techniques. The research presented here opens a
new avenue for small animal imaging research, as well as for
imaging patients in clinics.
In this research, we have evaluated three radionuclides (
18F,
131I, and
90Y) for small animal radioactive OI because of their
important roles in nuclear medicine.
18F is the most often used
PET radionuclide [20], and
131I and
90Y are two most widely used
radionuclides for radiotherapy [21,22]. In vivo optical images with
reasonable sensitivity can be quickly obtained for all three
radionuclides. These encouraging results suggest that the radio-
active OI can be a powerful tool for fast preliminary evaluation of
18F,
131I, and
90Y labeled compounds. This will be important for
90Y based agents development, since it has been relatively difficult
to obtain in vivo information for a
90Y agent through non-invasive
imaging method.
Compared to conventional fluorescence and bioluminescence
imaging, radioactive OI has some unique properties. It has wide
emission spectrum as demonstrated here, so that a radioactive
probe can be monitored at different wavelengths. More impor-
tantly, radioactive OI does not require excitation light, which is a
significant advantage over traditional OI. The radioactive OI
signal generated by a radioactive probe is constitutive, which is
Figure 4. Dual modality Na
18F imaging. Radioactive OI (A) and microPET imaging (B) of Na18F at 0.5, 1, 2 h after i.v. injection. Quantitative
analysis of radioactive OI (C) and microPET (D) results.
doi:10.1371/journal.pone.0009470.g004
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radioactive OI can be performed by monitoring spectral windows
that differ from typical FLuc spectrum. Therefore, it is possible to
perform BLI and radioactive OI in the same animal with proper
emission filters. Radionuclides also generally emit low levels of
light and are not expected to interfere with BLI.
It should be noted that although only b
+ and b
2 emitters were
evaluated in this study, many radionuclides (a, b
+, b
2, electron
capture, etc.) which emit charged particles are likely to be suitable
for OI. The detection and imaging sensitivity depends on the
physical properties of radionuclides, particularly their energy. As
shown in this study, the radionuclide with higher energy generates
stronger optical signals. Radioactive OI shares some common
disadvantages as other OI techniques: limited tissue penetration
and relatively poor quantification ability compared to PET and
SPECT. However, subcutaneous tumor models and superficial
disease models have been widely used in the medical research. For
these models, our results indicate, radioactive OI is a suitable
technique. Despite the stated disadvantages, OI techniques have
advanced rapidly over the past couple of years. OI has evolved
from a basic research tool to a modality which has great potential
utility for patient imaging. For instance, fluorescence molecular
tomography (FMT) and optical fiber based technology could
potentially lead to deeper tissue imaging. These techniques may be
very helpful for achievement of deeper tissue imaging with
radioactive OI as well. Future research in radioactive OI would
further accelerate the translation of OI into clinical application.
The optical signals detected could be originating from
Bremsstrahlung or Cerenkov radiation. Bremsstrahlung radiation
is a well-known physical phenomenon, which refers to the
electromagnetic radiation produced by slowing down or deflection
of charged particles (especially electrons) in the Coulomb fields of
atomic nuclei [23,24] In Cerenkov radiation, optical signal is
emitted when a charged particle travels through an insulator at a
speed greater than the speed of light in that medium [25,26]. Both
of them have continuous energy spectra in optical and NIR range
and are generated by radioactive disintegration of a charged
particle [23,24,25,26]. The recent publication on radioactive OI
by Robertson et al. strengthens our data. They propose Cerenkov
radiation as the origin of the optical signals generated from
positron emitting nuclides [6]. Cerenkov radiation was supported
by the following data: (1) The obtained radioactive optical
spectrum and (2) the increased light output as the refractive index
of medium increases. Initially, we assigned generation lumines-
cence signal to Cerenkov radiation as well. We obtained similar
results which optical signal strength was enhanced with increasing
Figure 5. In vivo radioactive OI of Na
131I compared to SPECT/CT imaging. Coronal (A) and sagittal (B) images of SPECT/CT imaging at 1 h
after injection of Na
131I probe. (C) Radioactive OI of a normal mouse at 0.5, 1, 12, 24 h after injection of Na
131I via tail vein. (D) Radioactive OI of a
normal mouse after opening the thorax 24 h post injection of Na
131I. (E) Quantitative analysis (n=3) of thyroid uptake of Na
131I from radioactive OI
results.
doi:10.1371/journal.pone.0009470.g005
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from IVIS system (Fig. 1) were quite different from the calculated
Cerenkov emission in literature [26]. Radioluminescence intensi-
ties, measured with a Fluoro Max-3 spectrofluorometer (Jobin
Yvon Inc., Edison, NJ), were consistent with the spectra obtained
from the IVIS system (Fig. S2). Moreover, water has a refractive
index of 1.332. The lower energy threshold for the emission of
Cerenkov radiation in water is thus calculated to be 263 KeV
[26]. However, radioactive optical signals could also be observed
for
111In, which emits particles with the energy below the
theoretical threshold. All these data imply that other mechanisms
such as Bremsstrahlung radiation may also contribute to the
radioactive OI. It is unclear as for the role of Bremsstrahlung
radiation compared to Cerenkov. The mechanism of radioactive
OI still needs to be further investigated.
Materials and Methods
Materials
Na
131I, Na
125I,
90YCl3, and
111InCl3 were purchased from
Perkin Elmer (Waltham, MA). Sodium pertechnetate
(Na
99mTcO4) was obtained from GE Healthcare Nuclear
Pharmacies (Sunnyvale, CA),
177LuCl3 and
64CuCl2 was provided
by the University of Missouri Research Reactor (Columbia, MO)
and the Department of Medical Physics, University of Wisconsin
at Madison (Madison, WI), respectively. [
18F]FDG and Na
18F
were produced by Radiochemistry Facility at Stanford University
(Stanford, CA). Heterodimer peptide DOTA-RGD-BBN was
provided by Dr. Xiaoyuan Chen as reported recently [15,16,17].
All other standard synthesis reagents were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO). Human prostate cancer
cell line PC3 was obtained from American Type Culture
Collection (Manassas, VA). Rat glioma cell C6-FLuc was from
Dr. Gambhir’s laboratory. Female athymic nude mice (nu/nu),
obtained from Charles River Laboratories, Inc. (Cambridge, MA)
were at 4–6 weeks of age. All instruments including electrospray
ionization mass spectrometry (ESI-MS), reverse phase high
performance liquid chromatography (RP-HPLC), PET dose
calibrator, and tumor cell lines are the same as described in our
previous publication [27].
Tumor Models
All animal studies were carried out in compliance with Federal
and local institutional rules for the conduct of animal experimen-
tation. C6-FLuc cells were cultured in DMEM medium supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin (Invitrogen Life Technologies, Carlsbad, CA). PC3
cells were cultured in F-12K medium with 2 mM L-glutamine
supplemented with 10% FBS and 1% penicillin-streptomycin. All
the cell lines were maintained in a humidified atmosphere of 5%
CO2 at 37uC, with the medium changed every other day. A 75%
confluent monolayer was detached with trypsin and dissociated into
a single cell suspension for further cell culture. Approximately
1610
6 C6-FLuc or PC3 cells suspended in PBS were implanted
subcutaneously in the flanks of nude mice. Tumors were allowed to
growntoasizeof500 to750 mg(2–3weeks),andthetumorbearing
mice were subjected to in vivo imaging and biodistribution studies.
In Vivo Bioluminescence Imaging
The mice bearing subcutaneous C6-FLuc tumors were
anesthetized in a chamber filled with 2% isofluorane in oxygen,
and then transferred to the light-tight chamber of the IVIS
Spectrum small animal imaging system (Caliper Life Sciences,
Hopkinton, MA). D-Luciferin was injected intraperitoneally and
the images were acquired at 10 min after injection.
Radioactive Optical Imaging
Radioactive OI was performed with an IVIS Spectrum system
(Caliper Life Science, Hopkinton, MA). For all in vivo and in vitro
Figure 6. In vivo radioactive OI of
90Y-RGD-BBN and
90YCl3. Radioactive OI (A) and quantitative analysis (n=3) (B)o f
90Y-RGD-BBN in mice
bearing PC3 tumor. (C,D) Receptor blocking studies of
90Y-RGD-BBN probe (at 1 h post-injection) using radioactive OI (C) and their quantification
analysis (n=3) (D). (E) Radioactive OI of
90YCl3 at various time points p.i.
doi:10.1371/journal.pone.0009470.g006
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(PBS; Invitrogen). Aliquots of 300 mL PBS solution with the
radionuclide were placed in each well of flat bottom 96-wells black
plates (Nunc, Naperville, IL) for in vitro studies. Wavelength-
resolved spectral imaging was carried out using an 18-set narrow
bands emission filters set (490–850 nm). Animals were placed in a
light-tight chamber under isofluorane anesthesia. Each acquisition,
with or without filters, took 1–5 min for all studies. Images were
acquired and analyzed using Living Image 3.0 software (Caliper
life sciences, Hopkinton, MA). Quantification of radioactive OI
images was corrected in accordance with the radionuclides’
respective physical decay properties. The dorsal skin area was
used as normal tissue representing muscle tissue for in vivo studies.
Optical signal was normalized to photons per second per
centimeter square per steradian (p/s/cm
2/sr). Identical setting
was used for in vitro Radioactive OI. For in vivo imaging study,
normal mice or mice bearing either C6-FLuc or PC3 (n=3 for
each imaging probe) were injected via tail vein with Na
18F (5.3–
5.7 MBq, 140–150 mCi), [
18F]FDG (10.4–11.3 MBq, 280–
305 mCi), Na
131I (2.2–2.3 MBq, 59–61 mCi),
90YCl3 (1.8–
2.0 MBq, 48–54 mCi) or
90Y-RGD-BBN (specific activity:
63 mCi/mg, 2.6–3.3 MBq, 70–90 mCi). For [
18F]FDG imaging
study, the mice were fasted over night prior to the experiment.
Phantom Studies
A Micro Deluxe phantom with different sized hot-rod inserts
(diameters, 1.2, 1.6, 2.4, 3.2, 4.0, and 4.8 mm) arranged in 6
segments (Data Spectrum Corp. Hillshorough, NC) was used for
phantom studies. The phantom was filled with 10 mL PBS with
[
18F]FDG (2.6 MBq, 70 mCi), Na
131I (2.2 MBq, 60 mCi) or
90YCl3 (1.9 MBq, 50 mCi). Radioactive OI was performed with
an exposure time of 1–3 min without filters. Images were
processed using Living Image 3.0 software.
PET Imaging
Small-animal microPET imaging of tumor-bearing mice was
performed on a small-animal PET R4 rodent model scanner
(Siemens Medical Solutions USA, Inc., Knoxville, TN). A group of
mice (n=3) bearing C6-FLuc were injected with [
18F]FDG (10.4–
11.3 MBq, 280–305 mCi) via tail vein. At 0.5, 1 and 2 h p.i., the
mice were anesthetized with 2% isofluorane (Aerrane’ Baxter,
Deerfield, IL), and placed in the prone position and near the
center of the field of view (FOV) of small-animal PET scanner.
Three-min static scans were obtained and the images were
reconstructed by a two-dimensional ordered subsets expectation
maximum (OSEM) algorithm. No background correction was
performed. The method for quantification analysis of the images
was the same as reported previously [27].
SPECT/CT Imaging
Images were obtained on an Imtek microCAT II/SPECT
system (Imtek, Inc. Knoxville, TN) at 1 h after injection of 2.2–
2.3 MBq
131I through tail vein. Computed tomography images
were acquired immediately after the SPECT scan. Co-registration
of CT and SPECT images was done using Amira software (Amira
3.1, Mercury Computer Systems GmbH, Berlin, Germany). No
X-ray contrast agent was used in this study.
Supporting Information
Figure S1 Radioactive optical signals increase in medium with
higher refractive indexes. Light outputs of 7 mCi
131I in various
media with different refractive indexes were imaged by IVIS
spectrum system in 96-well plates. (Refractive indexes: water,
1.333; 24% Glycerol, 1.363; 46% Glycerol, 1.392; 67% Glycerol,
1.423; 86% Glycerol, 1.452; DMSO, 1.479; DMF, 1.431.)
Found at: doi:10.1371/journal.pone.0009470.s001 (0.22 MB TIF)
Figure S2 Radioactive OI spectra of
90Y,
18F and
131I by Fluoro
Max-3. The spectra are consistent with those obtained by IVIS
spectrum imaging system.
Found at: doi:10.1371/journal.pone.0009470.s002 (0.37 MB TIF)
Acknowledgments
The authors gratefully thank Dr. Timothy C. Doyle for his technical
support on optical and SPECT/CT imaging and Dr. Xiaoyuan Chen for
providing the RGD-BBN peptide for this study.
Author Contributions
Conceived and designed the experiments: HL ZC. Performed the
experiments: HL GR ZM XZ. Analyzed the data: HL XT PH SSG ZC.
Wrote the paper: HL ZC.
References
1. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing
fundamental biological processes in a new light. Genes Dev 17: 545–580.
2. Gambhir SS (2002) Molecular imaging of cancer with positron emission
tomography. Nat Rev Cancer 2: 683–693.
3. Weissleder R (2006) Molecular imaging in cancer. Science 312: 1168–1171.
4. Weissleder R (2002) Scaling down imaging: molecular mapping of cancer in
mice. Nat Rev Cancer 2: 11–18.
5. Weissleder R, Ntziachristos V (2003) Shedding light onto live molecular targets.
Nat Med 9: 123–128.
6. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR, et al. (2009)
Optical imaging of Cerenkov light generation from positron-emitting radiotrac-
ers. Phys Med Biol 54: N355–365.
7. Shen S, DeNardo GL, Yuan A, DeNardo DA, DeNardo SJ (1994) Planar
gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl
Med 35: 1381–1389.
8. Siegel JA, Khan SH (1996) Body contour determination and validation for
bremsstrahlung SPECT imaging. J Nucl Med 37: 495–497.
9. Minarik D, Sjogreen Gleisner K, Ljungberg M (2008) Evaluation of quantitative
(90)Y SPECT based on experimental phantom studies. Phys Med Biol 53:
5689–5703.
10. Quon A, Gambhir SS (2005) FDG-PET and beyond: molecular breast cancer
imaging. J Clin Oncol 23: 1664–1673.
11. Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, et al. (2009) Novel
strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation
of malignancy: results of the pilot-phase study. J Nucl Med 50: 501–505.
12. Buscombe J, Hirji H, Witney-Smith C (2008) Nuclear medicine in the
management of thyroid disease. Expert Rev Anticancer Ther 8: 1425–1431.
13. Kogai T, Taki K, Brent GA (2006) Enhancement of sodium/iodide symporter
expression in thyroid and breast cancer. Endocr Relat Cancer 13: 797–826.
14. Chung JK (2002) Sodium iodide symporter: its role in nuclear medicine. J Nucl
Med 43: 1188–1200.
15. Liu Z, Li ZB, Cao Q, Liu S, Wang F, et al. (2009) Small-animal PET of
tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 50:
1168–1177.
16. Liu Z, Niu G, Wang F, Chen X (2009) (68)Ga-labeled NOTA-RGD-BBN
peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med
Mol Imaging 36: 1483–1494.
17. Liu Z, Yan Y, Chin FT, Wang F, Chen X (2009) Dual integrin and gastrin-
releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated
RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 52:
425–432.
18. Breeman WA, De Jong MT, De Blois E, Bernard BF, De Jong M, et al. (2004)
Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in
[90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+. Nucl Med Biol
31: 821–824.
19. Sevick-Muraca EM, Sharma R, Rasmussen JC, Marshall MV, Wendt JA, et al.
(2008) Imaging of lymph flow in breast cancer patients after microdose
administration of a near-infrared fluorophore: feasibility study. Radiology 246:
734–741.
20. Okarvi SM (2001) Recent progress in fluorine-18 labelled peptide radiophar-
maceuticals. Eur J Nucl Med 28: 929–938.
21. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K (2005) Current status of
cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 19:
355–365.
Radioactive Probes for OI
PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e947022. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, et al. (2009)
Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev En-
docrinol 5: 382–393.
23. Nakel W (1994) The elementary process of Bremsstrahlung. Physics Reports-
Review Section of Physics Letters 243: 317–353.
24. Seltzer SM, Berger MJ (1985) Bremsstrahlung Spectra from Electron
Interactions with Screened Atomic-Nuclei and Orbital Electrons. Nuclear
Instruments & Methods in Physics Research Section B-Beam Interactions with
Materials and Atoms 12: 95–134.
25. Cerenkov PA (1937) Visible radiation produced by electrons moving in a
medium with velocities exceeding that of light. Physical Review 52: 0378–0379.
26. Ross HH (1969) Measurement of Beta-Emitting Nuclides Using Cerenkov
Radiation. Analytical Chemistry 41: 1260–1265.
27. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, et al. (2008) Small-animal
PET imaging of human epidermal growth factor receptor type 2 expression with
site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49: 804–813.
Radioactive Probes for OI
PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9470